Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Abstract The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical…
Abstract The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical…
Abstract The endocannabinoid system (ECS) is a crucial modulatory system in which interest has been increasing, particularly regarding the regulation…
Abstract Stress is a frequent precipitant of relapse to drug use. Pharmacotherapies targeting a diverse array of neural systems have…
Abstract Neurodegenerative disorders affect fifteen percent of the world’s population and pose a significant financial burden to all nations. Cognitive…
Abstract Chronic kidney disease (CKD) concerns millions of individuals worldwide, with few therapeutic strategies available to date. Recent evidence suggests…
Abstract Elevated molecular stress in women is known to have negative impacts on the reproductive development of oocytes and the…
Abstract Chronic inflammation is considered to be a silent killer because it is the underlying cause of a wide range…
Abstract The present mini-review focuses on animal models of schizophrenia that have explored the effects of cannabidiol (CBD; a non-psychoactive…
Abstract While endocannabinoids (ECs) and cannabis were primarily studied for their nervous system effects, it is now clear that ECs…
Abstract Neutral cannabinoids are oxidatively unstable and are converted into quinone derivatives by atmospheric- and/or chemical oxidative dearomatization. The study…